MedPath

Effectiveness of phenytoin-caffeine combination in general seizure

Phase 2
Conditions
Epilepsy with general seizure
Registration Number
JPRN-UMIN000012255
Lead Sponsor
Directorate General of Higher Education, Ministry of Education and Culture
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

Diabetes Mellitus, acute or chronic myocard infarction, hypertension, chronic liver diseases

Study & Design

Study Type
Interventional,observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Seizure frequency, seizure reduction>50%, 6 month remission
Secondary Outcome Measures
NameTimeMethod
Plasma phenytoin concentration, and adverse drug reaction.
© Copyright 2025. All Rights Reserved by MedPath